Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 6Neuromyelitis Optica 2Recurrence 1Optic Neuritis 1Myelitis, Transverse 1Hemoglobinuria, Paroxysmal 1Demyelinating Diseases 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Whole-Body Irradiation 2Tacrolimus 2Methotrexate 2Cyclophosphamide 2treosulfan 1thymoglobulin 1ravulizumab 1X-Rays 1Sirolimus 1Observation 1Mycophenolic Acid 1Melphalan 1Etoposide 1Cyclosporine 1Busulfan 1Bone Marrow Transplantation 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoglobinuria, Paroxysmal × ravulizumab × 1 year × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔